Drug prices in Russia may increase by 20%-25% due to new labelling requirements

3 February 2017

Drug prices in Russia may increase by 20%-25% this year, due to the implementation of the latest state initiative for the introduction of mandatory QR-labelling on drugs in the local market, according to recent statements by local producers and analysts in the field of pharmaceutics, reports The Pharma Letrer’s local correspondent.

A pilot project was launched on February 1, and the new labeling requirements will become mandatory starting from January 1, 2018.

This has already sparked concerns from drugmakers and local pharmacy chains, according to which the new state initiative may result in a significant sales decline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK